



CellCept® IV (mycophenolate mofetil) – First-Time Generic

- On November 22, 2016, Par launched an [AP-rated](#) generic version of Genentech's [CellCept \(mycophenolate mofetil\)](#) injection for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.
 - CellCept should be used concomitantly with cyclosporine and corticosteroids.
- CellCept injection is an alternative dosage form to CellCept capsules, tablets and oral suspension. CellCept injection should be administered within 24 hours following transplantation. CellCept injection can be administered for up to 14 days; patients should be switched to oral CellCept as soon as they can tolerate oral medication.
- CellCept is currently available generically as a capsule, tablet, and an oral suspension. [Myfortic® \(mycophenolic acid\)](#) delayed-release tablets are also available generically.
 - The generic CellCept capsule, tablet and oral suspension formulations share the same indication as the intravenous formulation.
 - Myfortic is indicated for the prophylaxis of organ rejection in adult and pediatric patients (≥ 5 years of age who are at least 6 months post-transplant) receiving a kidney transplant.
- CellCept and Myfortic carry a boxed warning regarding embryofetal toxicity, malignancies and serious infections.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.